Sign in to view content

Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years

Stephen R. Russell, MD

Video
Published 2024

Related

Stem Cell Therapy for Retinal Disease: Where Are We Now?
Susanna S. Park, MD, PhD
Updates from the Field
2022
Pooled Safety Analysis and Immunogenicity of a Single Intravitreal Injection of JNJ-1887 (Gene Therapy, AAVCAGsCD59) in Patients With AMD
Christine Kay, MD
Annual Meeting Talks
2024
Elamipretide, a Mitochondria-Targeted Drug for the Treatment of Vision Loss
Scott W. Cousins, MD
Updates from the Field
2019

Category: Hereditary Retinal Disease & Genetics

See more